RE:RE:Clean cysto and interesting comments from Urologist 012009, you are correct, cost of treatment is huge...
In this link it said...
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide | 2024-12-23 | Investing News | Stockhouse -Anktiva(N-803+BCG) is currently the most expensive FDA-approved treatment for BCG-Unresponsive NMIBC CIS on the market today,
costing US$215K ($300K CAN) per year and requiring weekly dose over a six-week period. -It also said in this link....
Secondly, BCG is experiencing a global shortage, prompting ImmunityBIO to partner with the '' Serum Institute Of India'' to shore up BCG supply,
though their new strain has yet to receive FDA approval. -Anktiva (N-803+BCG) Duration Of Response at 24 Months is 24%.
Ruvidar Duration Of Response at 24 months is 36%,
( 50% more than Anktiva). -As we speak, as stand alone treatment Ruvidar is superior to Anktiva.
O12009 wrote: Good to hear your report was clean. I think it's Immunity Bio drug and BCG combo. The trial that just got BTD. I'm not sure how much it is being used. Cost of treatment is high and safety profile is not as good as TLT 1433